SCHEMBL772523

SCHEMBL772523

C[C@H](NC(=O)CCCC(=O)N1CCCC2CCCCC21)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PRCP P42785 3/20 0.50
NPC1 O15118 2/20 0.49
RAB9A P51151 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MAPT P10636 1/20 0.46
ALDH1A1 P00352 3/20 0.45
GAA P10253 2/20 0.45
HPGD P15428 1/20 0.45
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
HTR1A P08908 2/20 0.44
DRD2 P14416 2/20 0.44
HTR7 P34969 2/20 0.44
HTR6 P50406 2/20 0.44
LMNA P02545 2/20 0.44
EPHX1 P07099 2/20 0.44
DPP4 P27487 1/20 0.43
DPP8 Q6V1X1 1/20 0.43
DPP7 Q9UHL4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL771118 1.00 PRCP (0.50) PRCPNPC1RAB9ASMN1; SMN2MAPT
SCHEMBL802601 0.89 ALDH1A1 (0.49) PRCPNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL10138695 0.89 ALDH1A1 (0.53) NPC1RAB9ASMN1; SMN2MAPTALDH1A1
SCHEMBL771811 0.89 ALDH1A1 (0.53) NPC1RAB9ASMN1; SMN2MAPTALDH1A1
SCHEMBL803113 0.85 NPC1 (0.43) NPC1RAB9ASMN1; SMN2HPGDKMT2A
SCHEMBL772411 0.85 NPC1 (0.43) NPC1RAB9ASMN1; SMN2HPGDKMT2A
SCHEMBL770941 0.85 TAAR1 (0.47) NPC1RAB9ASMN1; SMN2HPGDKMT2A
SCHEMBL770362 0.85 NPC1 (0.45) NPC1RAB9ASMN1; SMN2ALDH1A1KMT2A
SCHEMBL771050 0.84 DPP4 (0.51) NPC1RAB9ASMN1; SMN2ALDH1A1KMT2A
SCHEMBL770883 0.84 DPP4 (0.46) NPC1RAB9ASMN1; SMN2DPP4DPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 PRCP 1922/4885NPC1 97/4885RAB9A 2187/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 PRCP 1940/4885NPC1 104/4885RAB9A 2217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.